Bart P. van de Warrenburg

Bart P. van de Warrenburg

Auto-generated profile, based on publicly available information

Bart P. van de Warrenburg

Department of Neurology, Donders Institute for Brain, Cognition, and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2018 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
ESEunju Seong
Eunju Seong
RIRyan Insolera
Ryan Insolera
MDMarija Dulovic
Marija Dulovic
EKErik‐Jan Kamsteeg
Erik‐Jan Kamsteeg
JTJoanne Trinh
Joanne Trinh
MBMargit Burmeister
Margit Burmeister

7 July 2015 in Neurology
Verified
Journal Article
Closed access
PDF file
RMRoderick P.P.W.M. Maas
Roderick P.P.W.M. Maas
JGJudith van Gaalen
Judith van Gaalen
TKThomas Klockgether
Thomas Klockgether
BWBart P.C. van de Warrenburg
Bart P.C. van de Warrenburg
The autosomal dominant spinocerebellar ataxias (SCAs) are a heterogeneous group of degenerative diseases of the cerebellum and connected regions. The discovery of various SCA genes and the subsequent possibility of predictive testing currently allow a genetic diagnosis to be established years or even decades before the actual appearance of ataxia symptoms. A growing body of evidence, however, indicates that this preclinical stage is subject to the earliest pathophysiologic changes. This review article comprehensively summarizes the studies conducted in preclinical carriers of a mutation in one of the SCA genes. From these data, it can indeed be concluded that the preclinical phase in SCA is already characterized by detectable central and peripheral nervous system changes, which are reflected by subtle abnormalities during a careful clinical examination, changes in structural and functional brain imaging, abnormal neurophysiologic measurements, and/or altered motor learning paradigms. As these may be compensated for a long time, ataxia symptoms probably only appear after a certain threshold of dysfunction or degeneration has been exceeded. Detailed knowledge of this disease stage is of particular relevance for a better understanding of the pathogenesis of SCAs, will allow us to determine the optimal point in time for interventions in future therapeutic trials, and points to objective, valid biomarkers to assess disease progression. Further studies will benefit from a consensus-based definition of the preclinical stage, from using one and the same validated ataxia rating scale with one fixed cutoff value, and from applying similar mathematical models to calculate time to predicted disease onset.

17 July 2019 in BMC Neurology
Verified
Journal Article
Open access
PDF file
BBBas R. Bloem
Bas R. Bloem
WMW. J. Marks
W. J. Marks
ALA. L. Silva de Lima
A. L. Silva de Lima
MKM. L. Kuijf
M. L. Kuijf
TLTeus Van Laar
Teus Van Laar
MMM. J. Meinders
M. J. Meinders
Our understanding of the etiology, pathophysiology, phenotypic diversity, and progression of Parkinson’s disease has stagnated. Consequently, patients do not receive the best care, leading to unnecessary disability, and to mounting costs for society. The Personalized Parkinson Project (PPP) proposes an unbiased approach to biomarker development with multiple biomarkers measured longitudinally. Our main aims are: (a) to perform a set of hypothesis-driven analyses on the comprehensive dataset, correlating established and novel biomarkers to the rate of disease progression and to treatment response; and (b) to create a widely accessible dataset for discovery of novel biomarkers and new targets for therapeutic interventions in Parkinson’s disease. This is a prospective, longitudinal, single-center cohort study. The cohort will comprise 650 persons with Parkinson’s disease. The inclusion criteria are purposely broad: age ≥ 18 years; and disease duration ≤5 years. Participants are followed for 2 years, with three annual assessments at the study center. Outcomes include a clinical assessment (including motor and neuro-psychological tests), collection of biospecimens (stool, whole blood, and cerebrospinal fluid), magnetic resonance imaging (both structural and functional), and ECG recordings (both 12-lead and Holter). Additionally, collection of physiological and environmental data in daily life over 2 years will be enabled through the Verily Study Watch. All data are stored with polymorphic encryptions and pseudonyms, to guarantee the participants’ privacy on the one hand, and to enable data sharing on the other. The data and biospecimens will become available for scientists to address Parkinson’s disease-related research questions. The PPP has several distinguishing elements: all assessments are done in a single center; inclusion of “real life” subjects; deep and repeated multi-dimensional phenotyping; and continuous monitoring with a wearable device for 2 years. Also, the PPP is powered by privacy and security by design, allowing for data sharing with scientists worldwide respecting participants’ privacy. The data are expected to open the way for important new insights, including identification of biomarkers to predict differences in prognosis and treatment response between patients. Our long-term aim is to improve existing treatments, develop new therapeutic approaches, and offer Parkinson’s disease patients a more personalized disease management approach. Clinical Trials NCT03364894 . Registered December 6, 2017 (retrospectively registered).

13 January 2014 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
BWB. P. C. van de Warrenburg
B. P. C. van de Warrenburg
JGJ. van Gaalen
J. van Gaalen
SBS. Boesch
S. Boesch
JBJ.‐M. Burgunder
J.‐M. Burgunder
ADA. Dürr
A. Dürr
ORO. Riess
O. Riess

14 May 2018 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
MRMalco Rossi
Malco Rossi
MAMathieu Anheim
Mathieu Anheim
ADAlexandra Durr
Alexandra Durr
CKChristine Klein
Christine Klein
MKMichel Koenig
Michel Koenig
ODon behalf of the International Parkinson and Movement Disorder Society Task Force on Classification and Nomenclature of Genetic Movement Disorders
on behalf of the International Parkinson and Movement Disorder Society Task Force on Classification and Nomenclature of Genetic Movement Disorders

18 July 2023 in Sensors
Verified
Journal Article
Open access
PDF file
CHChang Soon Tony Hii
Chang Soon Tony Hii
Kok Beng GanKok Beng Gan
Kok Beng Gan
NZNasharuddin Bin Zainal
Nasharuddin Bin Zainal
NINorlinah Mohamed Ibrahim
Norlinah Mohamed Ibrahim
SAShahrul Azmin
Shahrul Azmin
HYHuay Woon You
Huay Woon You
Gait analysis is an essential tool for detecting biomechanical irregularities, designing personalized rehabilitation plans, and enhancing athletic performance. Currently, gait assessment depends on either visual observation, which lacks consistency between raters and requires clinical expertise, or instrumented evaluation, which is costly, invasive, time-consuming, and requires specialized equipment and trained personnel. Markerless gait analysis using 2D pose estimation techniques has emerged as a potential solution, but it still requires significant computational resources and human involvement, making it challenging to use. This research proposes an automated method for temporal gait analysis that employs the MediaPipe Pose, a low-computational-resource pose estimation model. The study validated this approach against the Vicon motion capture system to evaluate its reliability. The findings reveal that this approach demonstrates good (ICC(2,1) > 0.75) to excellent (ICC(2,1) > 0.90) agreement in all temporal gait parameters except for double support time (right leg switched to left leg) and swing time (right), which only exhibit a moderate (ICC(2,1) > 0.50) agreement. Additionally, this approach produces temporal gait parameters with low mean absolute error. It will be useful in monitoring changes in gait and evaluating the effectiveness of interventions such as rehabilitation or training programs in the community.